On March 7, 2017 on KTVB Channel 7 Local News, there was a story about a new transmittable virus that effects babies but the babies show no symptoms. The name of the virus is Cytomegalovirus (CMV). The reason for the use of the word new is because it is something that few people have heard of before now. There is a couple in Idaho who have a daughter who allegedly has this virus. Her parents started a Foundation to educate people and the health care community about it. The Idaho legislature passed a bill recognizing the virus and they appropriated money for educational materials to distribute around the state. Apply some logic and common sense to that and it doesn’t compute.
This is my worst nightmare come true since 2007 when I began writing about the Human Genome Project in conjunction with the redesign of our health care system – the emergence of a new unheard of disease that shows no symptoms but is preventable and treatable and supposedly a significant percentage of the population has it. It’s the perfect diagnosis for applied genetics research on an unsuspecting population and the redesign of our health care system with nationalized medical records was designed to accommodate it. In 2009 when I heard the name Project Destiny and I researched it and found that it had to do with the pharmaceutical profession, it was simply further confirmation that my instincts in 2007 and my subsequent research to find the elements of the system design that would enable it were correct.
Project Destiny was a strategic plan to add a new role in health care for your local pharmacist. On August 15, 2007, Medical News Today reported that the Pharmaceutical Industry Supports Visionary Project Destiny Initiative, USA. Project Destiny required a new specialty be approved by the Board of Pharmaceutical Specialties. It was announced in March of 2008 in an article titled Pharmacy Groups Unveil Findings, Future of “Project Destiny”.
The stated objective of Project Destiny is to develop a replicable, scalable, measurable, and economically viable future model for community pharmacy. The project seeks to identify ways that patients and the healthcare system can benefit from community pharmacy’s medication expertise, in a way that is economically viable for all parties.
One key concept that emerged from the first phase of the project is that of a “primary care pharmacist,” who would work collaboratively with the healthcare delivery and financing systems and focus on managing medications, positively impacting health outcomes, reducing overall healthcare system costs and empowering consumers to actively manage their health. Putting this concept into practice would require the development of pharmacy-based Patient Care Management Services that are consistent nationwide while maintaining the autonomy of individual pharmacies.
A pharmacist as medication manager and front line health care provider fits into the agenda of applied genetics research because in order to personalize medications for a person’s DNA requires customized drugs which means a compounding pharmacist (maker of drugs) and access to the medical record and a say in the patient’s care. Project Destiny fulfills that requirement.
The Vision for the Future
Project Destiny has developed the following proposed vision for community pharmacy:
Community pharmacists will fulfill the role of a primary care pharmacist, serving as a trusted and effective resource that is valued by consumers, prescribers, healthcare funders and payers for their clinical and medical management expertise.
The primary care pharmacist will demonstrate their value working with consumers to navigate throughout the healthcare delivery system and improve health outcomes through better medication and condition management.
Working collaboratively with the healthcare delivery and financing systems, the primary care community pharmacist will focus on managing medications, positively impacting health outcomes, reducing overall healthcare system costs and empowering consumers to actively manage their health.
To realize the vision for community pharmacy, Project Destiny developed potential models for consideration, which focused on:
Delivering the vision of a new Community Pharmacy Service Model …
Pharmacies across geographies can choose to deliver a core service offering of Patient Care Management Services to consumers in collaboration with payers regardless of which type of community pharmacy the consumer selects.
Fostering a consistent infrastructure based on appropriately adopted standards…
Appropriately adopted standards will help ensure service obligations to consumers and payers are met and will help ensure efficient operational delivery within a pharmacy organization providing services to multiple consumers and payers.
Maintaining the autonomy of individual pharmacies
• Independent pricing and contracting at the pharmacy organization level
• The ability to enhance the core elements at the pharmacy organization level.
This morning when I was looking on the Idaho Legislature website for the legislation to support the education initiative for this unknown, symptomless viral disease called Cytomegalovirus, I found a couple of other related health care bills:
BY HEALTH AND WELFARE COMMITTEE
RELATING TO PHARMACISTS; AMENDING SECTION 54-1723, IDAHO CODE, TO REVISE
PROVISIONS REGARDING RECIPROCAL LICENSING AND TO MAKE A TECHNICAL CORRECTION.
54-1723. QUALIFICATIONS FOR LICENSURE BY RECIPROCITY.
(1) To obtain a license as a pharmacist by reciprocity….
The other related piece of legislation has to do with visas for foreign doctors:
BY HEALTH AND WELFARE COMMITTEE
RELATING TO THE IDAHO CONRAD J-1 VISA WAIVER PROGRAM…
SECTION 1. That Section 39-6102, Idaho Code, be, and the same is hereby amended to read as follows:
39-6102. PURPOSE. Under this chapter, rural and underserved communities in Idaho would be able to apply for the placement of a foreign trained physician after demonstrating that they are unable to recruit an American physician, and all other recruitment/placement possibilities have proven to be inaccessible.
(1) The “Idaho Conrad J-1 Visa Waiver Program” authorizes the Idaho department of health and welfare to recommend up to thirty (30) foreign trained physicians per federal fiscal year to locate in communities that are federally designated as having a health workforce shortage…
(3) The “National Interest Waiver Program” allows the Idaho department of health and welfare to testify that it is in the public’s interest that a waiver be granted to a foreign trained physician who commits to locating in a community that is federally determined as having a health workforce shortage. Final approval of the national interest waiver request is made by the United States bureau of citizenship and immigration services.
(10) “J-1 visa” means an entrance permit into the United States for a foreign trained physician who is a nonimmigrant admitted under section 101(a)(15)(J) of the United States information and education exchange act or who acquired such status or who acquired exchange visitor status under the act.
(11) “J-1 visa waiver” means a federal action that waives the requirement for a foreign physician, in the United States on a J-1 visa, to return to his home country for a two (2) year period following medical residency training.
(12) “National interest waiver” means an exemption from the labor certification process administered by the United States department of labor for foreign physicians whose will to stay in the United States and work in an area of underservice in Idaho is determined to be in the public interest by the Idaho department of health and welfare.
SECTION 18. An emergency existing therefor, which emergency is hereby declared to exist, this act shall be in full force and effect on and after its passage and approval.
The nature of this so-called emergency is found in the resolution the Idaho Legislature passed that recognized this unknown disease Cytomegalovirus (CMV) that nobody ever heard of before now. Lines 16 and 17 of House Concurrent Resolution 9 links together the agenda:
BY HEALTH AND WELFARE COMMITTEE
A CONCURRENT RESOLUTION STATING FINDINGS OF THE LEGISLATURE
AND SUPPORTING EFFORTS TO ALLEVIATE THE
EFFECTS OF RARE DISEASES ON IDAHOANS.
WHEREAS, there are only eight pediatric neurologists in Idaho, six of 15 whom practice in Boise;
WHEREAS, pediatric physicians and neurologists have an average waiting list of eight to nine weeks; and
WHEREAS, once a diagnosis of “rare disease” is made, many Idaho patients are referred to neurological clinics in surrounding states for evaluation and treatment…
The monsters who are behind the redesign of our health system for the purpose of genetic research that I’ve been writing about for ten years are now coming for the babies. Don’t let this happen.